Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov 10;16(1):217.
doi: 10.1186/s12883-016-0742-9.

Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40

Yuetiva Deming  1 , Kathleen Black  1 , David Carrell  1 , Yefei Cai  1 , Jorge L Del-Aguila  1 , Maria Victoria Fernandez  1 , John Budde  1 , ShengMei Ma  1 , Benjamin Saef  1 , Bill Howells  1 , Sarah Bertelsen  2 , Kuan-Lin Huang  3 , Courtney L Sutphen  4 , Rawan Tarawneh  4   5   6 , Anne M Fagan  4   5   6 , David M Holtzman  4   5   6   7 , John C Morris  4   5   6   7 , Alison M Goate  2 , Joseph D Dougherty  1   3 , Carlos Cruchaga  8   9
Affiliations

Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40

Yuetiva Deming et al. BMC Neurol. .

Abstract

Background: Alzheimer's disease (AD) pathology appears several years before clinical symptoms, so identifying ways to detect individuals in the preclinical stage is imperative. The cerebrospinal fluid (CSF) Tau/Aβ42 ratio is currently the best known predictor of AD status and cognitive decline, and the ratio of CSF levels of chitinase-3-like 1 protein (CHI3L1, YKL-40) and amyloid beta (Aβ42) were reported as predictive, but individual variability and group overlap inhibits their utility for individual diagnosis making it necessary to find ways to improve sensitivity of these biomarkers.

Methods: We used linear regression to identify genetic loci associated with CSF YKL-40 levels in 379 individuals (80 cognitively impaired and 299 cognitively normal) from the Charles F and Joanne Knight Alzheimer's Disease Research Center. We tested correlations between YKL-40 and CSF Tau/Aβ42 ratio, Aβ42, tau, and phosphorylated tau (ptau181). We used studentized residuals from a linear regression model of the log-transformed, standardized protein levels and the additive reference allele counts from the most significant locus to adjust YKL-40 values and tested the differences in correlations with CSF Tau/Aβ42 ratio, Aβ42, tau, and ptau181.

Results: We found that genetic variants on the CH13L1 locus were significantly associated with CSF YKL-40 levels, but not AD risk, age at onset, or disease progression. The most significant variant is a reported expression quantitative trait locus for CHI3L1, the gene which encodes YKL-40, and explained 12.74 % of the variance in CSF YKL-40 in our study. YKL-40 was positively correlated with ptau181 (r = 0.521) and the strength of the correlation significantly increased with the addition of genetic information (r = 0.573, p = 0.006).

Conclusions: CSF YKL-40 levels are likely a biomarker for AD, but we found no evidence that they are an AD endophenotype. YKL-40 levels are highly regulated by genetic variation, and by including genetic information the strength of the correlation between YKL-40 and ptau181 levels is significantly improved. Our results suggest that studies of potential biomarkers may benefit from including genetic information.

Keywords: Alzheimer disease; CHI3L1; Cerebrospinal fluid; YKL-40.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Manhattan and regional plots for associations with CSF levels of YKL-40. a Manhattan plot of –log10 p-values for genetic association with CSF levels of YKL-40; b Regional plot for genome-wide significant association on chromosome 1
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Tarawneh R, Head D, Allison S, Buckles V, Fagan AM, Ladenson JH, Morris JC, Holtzman DM. Cerebrospinal fluid markers of neurodegeneration and rates of brain atrophy in early Alzheimer disease. JAMA Neurol. 2015;72(6):656–665. doi: 10.1001/jamaneurol.2015.0202. - DOI - PMC - PubMed
    1. Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE, Roe CM, Peskind ER, Li G, Galasko DR, et al. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS One. 2011;6(1):e16032. doi: 10.1371/journal.pone.0016032. - DOI - PMC - PubMed
    1. Price JL, Morris JC. Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease. Ann Neurol. 1999;45(3):358–368. doi: 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X. - DOI - PubMed
    1. de Jong D, Jansen RW, Kremer BP, Verbeek MM. Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia. J Gerontol A Biol Sci Med Sci. 2006;61(7):755–758. doi: 10.1093/gerona/61.7.755. - DOI - PubMed
    1. Harari O, Cruchaga C, Kauwe JS, Ainscough BJ, Bales K, Pickering EH, Bertelsen S, Fagan AM, Holtzman DM, Morris JC, et al. Phosphorylated tau-Abeta42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid. Biol Psychiatry. 2014;75(9):723–731. doi: 10.1016/j.biopsych.2013.11.032. - DOI - PMC - PubMed